C9orf72 and amyotrophic lateral sclerosis: These include Synucleozid for PD (Zhang et al., 2020), Mitoxantrone for primary tauopathies (Zheng et al., 2009), and at least one compound with the ability to target expanded repeat regions of FMR1 mRNA and C9orf72 mRNA, involved in FXTAS and c9FTD/ALS, respectively (Colak et al., 2014; Su et al., 2014; Wang et al., 2019).